DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Visipaque (Iodixanol Intravascular) - Summary

 
 



VISIPAQUE SUMMARY

VISIPAQUE™
(iodixanol) Injection
     320

VISIPAQUE™ (iodixanol) Injection, 5,5'-[(2-hydroxy-1,3-propanediyl)bis (acetylimino)]bis[N,N'-bis(2,3-dihydroxypropyl)-2,4,6- triiodo-1,3- benzenedicarboxamide], is a dimeric, isosmolar, nonionic, water-soluble, radiographic contrast medium with a molecular weight of 1550.

INTRA-ARTERIAL

VISIPAQUE Injection (270 mgI/mL) is indicated for intra-arterial digital subtraction angiography.

VISIPAQUE Injection (320 mgI/mL) is indicated for angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography.

INTRAVENOUS [For information on the concentrations and doses for the pediatric population see the Precautions–Pediatric Use, Clinical Pharmacology–Special Populations, and Dosage and Administration sections.]

VISIPAQUE Injection (270 mgI/mL) is indicated for CECT imaging of the head and body, excretory urography, and peripheral venography.

VISIPAQUE Injection (320 mgI/mL) is indicated for CECT imaging of the head and body, and excretory urography.


See all Visipaque indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Visipaque (Iodine Intravascular)

Rapid diagnostics for multidrug resistant organisms in combat-related infection
Source: MRSA / Drug Resistance News From Medical News Today [2016.05.10]
The occurrence of multidrug resistant infection is a major concern in Wounded Warriors and military Veterans, especially in combat-related injuries.

Zika: Portable, rapid diagnostic test could reach clinical use in months
Source: Tropical Diseases News From Medical News Today [2016.05.06]
Researchers have created a low-cost, portable test that has been shown to quickly detect Zika virus in infected monkeys. They say it could reach clinical use in several months.

Thyroid Cancer Cases in U.S. Level Off, Perhaps Reflecting Diagnostic Changes
Source: MedicineNet Thyroid Cancer Specialty [2016.04.15]
Title: Thyroid Cancer Cases in U.S. Level Off, Perhaps Reflecting Diagnostic Changes
Category: Health News
Created: 4/14/2016 12:00:00 AM
Last Editorial Review: 4/15/2016 12:00:00 AM

Flexible future of point-of-care disease diagnostic
Source: Bird Flu / Avian Flu News From Medical News Today [2015.07.29]
The world-wide deployment of biomedical devices for health monitoring, point-of-care diagnostics and environmental sensing is hampered by their high cost that is not readily affordable for e.g.

Time to Colonoscopy Counts After Positive Stool Test
Source: Medscape Gastroenterology Headlines [2016.05.20]
When diagnostic colonoscopy after a positive fecal immunochemical test is delayed beyond 6 months, the risk for colorectal cancer increases, new research suggests.
Medscape Medical News

more news >>

Published Studies Related to Visipaque (Iodine Intravascular)

Alcohol-based chlorhexidine vs. povidone iodine in reducing skin colonization prior to regional anesthesia procedures. [2011.07]
CONCLUSION: For skin disinfection prior to the neuraxial blockade procedure, the use of alcohol-based chlorhexidine compared with the use of povidone iodine lowered the incidence of insertion-site-colonization.

MDCT angiography for detection of pulmonary emboli: comparison between equi-iodine doses of iomeprol 400 mgI/mL and iodixanol 320 mgI/mL. [2009.06]
OBJECTIVES: To compare iomeprol 400 and iodixanol 320 in pulmonary artery MDCTA in subjects with suspected pulmonary embolism... CONCLUSION: The greater iodine delivery rate achievable with iomeprol 400 compared to iodixanol-320 at equi-iodine dose and injection rate permits consistently greater attenuation at all levels of the pulmonary arterial tree.

Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. [2006.09.05]
OBJECTIVES: This study sought to compare the nephrotoxicity of iodixanol and ioxaglate in patients with renal impairment undergoing coronary angiography. BACKGROUND: Iodixanol, a nonionic, dimeric, iso-osmolar contrast medium (IOCM), may be less nephrotoxic than low-osmolar contrast media (LOCM) in high-risk patients... CONCLUSIONS: The IOCM iodixanol was significantly less nephrotoxic than ioxaglate, an ionic, dimeric LOCM. (The RECOVER Trial; http://clinicaltrials.gov; NCT00247325).

Intravenous contrast material administration at helical 16-detector row CT coronary angiography: effect of iodine concentration on vascular attenuation. [2005.08]
The institutional review board approved this study, and all patients gave written informed consent. One hundred twenty-five patients scheduled to undergo retrospectively electrocardiographically gated 16-detector row computed tomographic coronary angiography were prospectively randomized into the following five groups with respect to the intravenous administration of a 140-mL bolus of contrast material at 4 mL/sec: group 1 (iohexol [300 mg of iodine per milliliter]), group 2 (iodixanol [320 mg I/mL]), group 3 (iohexol [350 mg I/mL]), group 4 (iomeprol [350 mg I/mL]), and group 5 (iomeprol [400 mg I/mL])...

Coronary stent evaluation with coronary computed tomographic angiography: comparison between low-osmolar, high-iodine concentration iomeprol-400 and iso-osmolar, lower-iodine concentration iodixanol-320. [2014]
stents with MDCT-CA... CONCLUSIONS: Iodixanol-320 provides better image quality of coronary stents,

more studies >>

Reports of Suspected Visipaque (Iodine Intravascular) Side Effects

Pyrexia (10)Renal Failure Acute (10)Infusion Site Extravasation (7)Hyperkalaemia (6)Headache (6)Lactic Acidosis (6)Nausea (6)Diarrhoea (6)Abdominal Pain (5)Confusional State (5)more >>


Page last updated: 2016-05-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015